Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Go back to Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
SAREPTA THERAP (NASDAQ: SRPT) Delayed: 22.23 +1.29 (6.16%)
Previous Close $20.94    52 Week High $63.73 
Open $20.81    52 Week Low $8.00 
Day High $23.22    P/E N/A 
Day Low $20.63    EPS $-5.69 
Volume 2,368,977